KAZIA CONTINUES BOARD RENEWAL WITH TWO NEW APPOINTMENTS

/PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, is pleased to announce the appointment of pharma...

Related Keywords

Australia ,Temple University ,Pennsylvania ,United States ,Sydney ,New South Wales ,Philadelphia ,Lilly Bio ,Bryce Carmine ,John Friend ,Kazia Therapeutics Limited ,Genentech ,Global Pharmaceutical Product Development ,Arthur Andersen Company ,Eli Lilly Co ,Prnewswire Kazia Therapeutics Limited ,Drug Administration ,Antares Pharma Inc ,Lilly Executive Committee ,Kerathin Inc ,Paxmedica Inc ,Genaera Corporation ,Therapeutics Limited ,Robert Apple ,Antares Pharma ,Senior Vice President ,Chief Financial Officer ,Corporate Secretary ,Chief Executive Officer ,Halozyme Therapeutics ,Inkine Pharmaceutical ,Chief Operating ,Financial Officer ,Liberty Technologies ,Arthur Andersen ,Non Executive Director ,Kazia Board ,Eli Lilly ,Executive Vice President ,Global Pharmaceutical Sales ,Kazia Therapeutics ,Fast Track Designation ,Rare Pediatric Disease Designatio ,Orphan Designation ,Pharmaceuticals ,Health Care Amp Hospitals ,Medical Pharmaceuticals ,Personnel Announcements ,